Page 16 - ஆரம்ப நுழைவு ப்ரோக்ர்யாம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Message : Required fields TUCSON, Ariz., April 05, 2021 (GLOBE NEWSWIRE) HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today reported certain preliminary financial results for the first quarter ended March 31, 2021. As discussed during HTG’s earnings conference call on March 25, the company believes its full year 2021 revenue could grow 30% to 40% over 2020 levels as it navigates a resurgence of COVID-19, which impacted the first quarter and is expected to continue to impact at least the first half of 2021. HTG expects to report unaudited total revenue for the first quarter ended March 31, 2021 of approximately $1.4 million, and cash, cash equivalents and short-term marketable securities of approximately $30.8 million as of March 31, 2021.

Ashley robinsonJohn lubniewskiExchange commissionEarly adopter programEarly access programMolecular diagnostics incHarbor statementPrivate securities litigation reform actAnnual reportஆஷ்லே ராபின்சன்பரிமாற்றம் தரகுஆரம்ப நுழைவு ப்ரோக்ர்யாம்மூலக்கூறு பரிசோதனை இன்க்துறைமுகம் அறிக்கைப்ரைவேட் பத்திரங்கள் வழக்கு சீர்திருத்தம் நாடகம்ஆண்டு அறிக்கை